Esphera SynBio Inc
Brian Lichty is a prominent figure in the biotechnology and academic sectors, currently serving as Scientific CoFounder and CEO at both Esphera SynBio Inc, where a platform technology for the generation of designer exosomes is being developed, and AeroImmune Inc, focusing on inhaled vaccines and antivirals. Lichty is also an Associate Professor at McMaster University and a member of the Board of Directors for McMaster Health Labs. Previously, Lichty co-founded Turnstone Biologics, serving as CTO followed by SVP of Basic Research, and gained valuable experience as a Postdoctoral Fellow at the Ottawa Health Research Institute. Academic credentials include a PhD in Pathology from the University of Toronto and an HBSc in Molecular Biology & Genetics from the University of Guelph.
This person is not in any teams
This person is not in any offices
Esphera SynBio Inc
Esphera SynBio is developing next-generation cancer and immunoregulatory treatments through its innovative synthetic biology platform. The company develops advanced nanomedicines in the form of functionalized vesicles, which can be produced either in vitro or in vivo through their proprietary transgene technology. Esphera’s lead clinical candidate represents a novel approach in cancer immunotherapy - an off-the-shelf treatment that triggers tumor cells to generate a bespoke personalized cancer vaccine in vivo. Beyond oncology, Esphera's versatile platform shows promise in broader immunomodulation applications.